AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...

WILMINGTON, Del., December 06, 2024--(BUSINESS WIRE)--AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI ® (durvalumab) has been accepted and granted Priority Review in ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license ...

小细胞肺癌 （SCLC） 是一种恶性程度高、侵袭性强的肺癌亚型，整体预后极差。据《中国肿瘤临床》，全球每年有超过20万例患者新发确诊SCLC，约占肺部恶性肿瘤总发病率的15%～20%，其中30%～40%处于局限期 （LS-SCLC） ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...

华盛顿 - ...

Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI®(durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle ...

Imfinzi (durvalumab) has been recommended by the National Institute for Health and Care Excellence (NICE) for the treatment ...

AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.